Synergistic effects of thalidomide and poly(ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice

Inflammation

Volumn 20, Issue 2, 1996, Pages 203-215

  Kröger, Hans ^a   Miesel, Ralf ^a,b   Dietrich, Annette ^a   Ohde, Manuela ^a   Rajnavölgyi, Eva ^a   Ockenfels, Heinrich ^c  

^a German Rheumatology Research Center   (Germany)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN ANTIBODY; COLLAGEN TYPE 2; ENZYME INHIBITOR; HYPNOTIC SEDATIVE AGENT; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTHRITIS; ARTICLE; BLOOD; CHEMOLUMINESCENCE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DRUG POTENTIATION; HUMAN; INTRAGASTRIC DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN;

ANIMALS; ARTHRITIS; ARTHRITIS, RHEUMATOID; CATTLE; COLLAGEN; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; IMMUNIZATION; ISOANTIBODIES; MALE; MICE; MICE, INBRED DBA; NADPH OXIDASE; NEUTROPHILS; NIACINAMIDE; POLY(ADP-RIBOSE) POLYMERASES; RESPIRATORY BURST; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 0029926570     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf01487406     Document Type: Article

References (43)

1. GUTIÉRREZ-RODRÍGUEZ, O., P. STARUSTA-BACAL, and O. GUTIÉRREZ-MONTES. 1989. Treatment of refractory rheumatoid arthritis - the thalidomide experience. J. Rheumatol. 16:158-163.
2. ATRA, E., and E. I. SATO. 1993. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin. Exp. Rheumatol. 11:487-493.
3. SCHWINGHAMMER, T. L., and E. J. BLOOM. 1993. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation. Clin. Pharm. 12:736-761.
4. HANDLEY, J., M. SHIELDS, J. DODGE, M. WALSH, and A. BINGHAM. 1993. Chronic bullous disease of childhood and ulcerative colitis. Pediat. Dermatol. 10:256-258.
5. MAKONKAWKEYOON, S., R. N. R. LIMSON-POBRE, A. L. MOREIRA, V. SCHAUF, and G. KAPLAN. 1993. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 90:5974-5978.
6. KAPLAN, G. 1993. Recent advances in cytokine therapy in leprosy. J. Infect. Dis. 167(Suppl. 1):S18-22.
7. EHNINGER, G., K. EGER, A. STUHLER, and U. SCHULER. 1993. Thalidomide - the need for a new clinical evaluation of an old drug. Bone Marrow Transplant. 12(Suppl. 3):S26-28.
8. MOREIRA, A. L., E. P. SAMPAIO, A. ZMUIDZINAS, P. FRINDT, K. A. SMITH, and G. KAPLAN. 1993. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J. Exp. Med. 177:1675-1680.
9. ELLIOTT, M. J., R. N. MAINI, M. FELDMANN, A. LONG-FOX, P. CHARLES, and F. M. BRENNAN. 1993. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNFα. Safety, clinical efficacy and regulation of the acute-phase response. Brit. J. Rheumatol. 32(Abstracts Suppl. 1):107.
10. KEFFER, J., L. PROBERT, H. CAZLARIS, S. GEORGOPOULOS, E. KASLARIS, D. KIOUSSIS, and G. KOLLIAS. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10:4025-4031.
11. KRÖGER, H., R. MIESEL, W. EHRLICH, and M. KURPISZ. 1994. Arthritogenic mechanisms of deregulated poly-ADP-ribosylation in experimental models of arthritis. Z. Rheumotol. 53(Suppl. 1):59.
12. MIESEL, R., M. KURPISZ, and H. KRÖGER. 1995. Modulation of inflammatory arthritis by inhibition of poly(ADP-ribose) polymerase. Inflammation 19:379-387.
13. KRÖGER, H., A. DIETRICH, M. OHDE, and R. MIESEL. 1995. Influence of antagonists of poly(ADP-ribose) polymerase on the development of collagen II induced arthritis. Submitted.
14. MIESEL, R., H. KRÖGER, M. ZUBER, R. GRÄTZ, and J. NETH. 1994. Elevated levels of oxygen-and nitrogen-centered radicals in patients with inflammatory and autoimmune rheumatic diseases. Z. Rheumatol. 53(Suppl. 1):6.
15. DE MURCIA, G., M. JACOBSON, and S. SHALL. 1995. Regulation by ADP-ribosylation. Trends Cell Biol. 5:78-81.
16. MIESEL, R., M. ZUBER, R. HARTUNG, and H. KRÖGER. 1995. Total radical trapping antioxidative capacity of plasma and whole blood chemiluminescence in patients with inflammatory and autoimmune rheumatic diseases. Redox Report, in press.
17. CARSON, D. A., S. SETO, and D. B. WASSON. 1986. Lymphocyte dysfunction after DNA damage by toxic oxygen species. J. Exp. Med. 163:746-751.
18. SIBLEY, J. T., R. P. BRAUN, and J. S. LEE. 1986. The production of antibodies to DNA in normal mice following immunization with poly(ADP-ribose). Clin. Exp. Immunol. 64:563-569.
19. KANAI Y., Y. KAWAMINAMI, M. MIWA, T. MATSUSHIMA, T. SUGIMURA, Y. MOROI, and R. YOKOHARI. 1977. Naturally-occurring antibodies to poly(ADP-ribose) in patients with systemic lupus erythematosus. Nature 265:175-177.
20. AGARWAL, S., and N. P. PIESCO. 1994. Poly ADP-ribosylation of a 90-kDa protein is involved in TNF-α-mediated cytotoxicity. J. Immunol. 153:473-481.
21. PELLAT-DECEUNYNCK, C., J. WIETZERBIN, and J. C. DRAPIER. 1994. Nicotinamide inhibits nitric oxide synthase mRNA induction in activated macrophages. Biochem. J. 297:53-58.
22. SHOCKETT, P., and J. STAVNEZER. 1993. Inhibitors of poly(ADP-ribose) polymerase increase antibody class switching. J. Immunol. 151:6962-6976.
23. AYER, L. M., S. M. EDWORTHY, and M. J. FRITZLER. 1993. Effect of procainamide and hydralazine on poly(ADP-ribosylation) in cell lines. Lupus 2:167-172.
24. HALLDÓRSSON, H., T. BÖDVARSDÓTTIR, M. KJELD, and G. THORGEIRSSON. 1992. Role of ADP-ribosylation in endothelial signal transduction and prostacyclin production. FEBS Lett. 314:322-326.
25. 2-superoxide dismutase. Rheumatol. Int. 14:119-126.
26. MIESEL, R., A. DIETRICH, N. ULBRICH, H. KROGER, and N. A. MITCHISON. 1994. Assessment of collagen type II induced arthritis in mice by whole blood chemiluminescence. Autoimmunity 19:153-159.
27. BOISSIER, M. C., G. CHIOCCHIA, M. C. RONZIERE, D. HERBAGE, and C. FOURNIER. 1990. Arthritogenicity of minor cartilage collagens (types IX and XI) in mice. Arthritis Rheum. 33: 1-8.
28. WOOLEY, P. H., H. S. LUTHRA, J. M. STUART, and C. S. DAVID. 1981. Type II collagen-induced arthritis in mice. J. Exp. Med. 154:688-700.
29. 99mpertechnetate-imaging. Free Radical Res. 23:213-227.
30. DIETRICH, A., N. A. MITCHISON, E. RAJNAVÖLGYI, and S. C. SCHNEIDER. 1994. Primed lymphocytes are boosted by type II collagen of their hosts after adoptive transfer. J. Autoimmunity 7:601-609.
31. MARCUS, R., and A. M. COULSTON. 1985. Nicotinic acid. In The pharmacological basis of therapeutics. A. Goodman Gilman, L. S. Goodman, T. W. Rall, and F. Murad, editors. 7th edition. Macmillan, New York. 1557-1559.
32. WOOLEY, P. H. 1988. Collagen-induced arthritis in the mouse. Methods Enzymol. 162:361-373.
33. MELLIN, G. W., and M. KATZENSTEIN. 1962. The saga of thalidomide. N. Engl. J. Med. 267:1184-1193.
34. MONCADA, B., M. L. BARANDA, R. GONZÁLEZ-AMARO, R. URBINA, and C. E. LOREDO. 1985. Thalidomide-effect on T cell subsets as a possible mechanism of action. Int. J. Lepr. 53:201-205.
35. VOGELSANG, G. B., S. TAYLOR, G. GORDON, and A. D. HESS. 1986. Thalidomide, a potent agent for the treatment of graft-versus-host disease. Transplant. Proc. 18:904-906.
36. BLASCHKE, G. 1986. Chromatographic resolution of chiral drugs on polyamides and cellulose triacetate. J. Liq. Chromatogr. 9:341-368.
37. TEIXEIRA, F., M. T. HOJYO, R. ARENAS, M. E. VEGA, R. CORTES, A. ORTIZ, and L. DOMINGUEZ. 1994. Thalidomide: can it continue to be used? Lancet 344:196-197.
38. NISHIMURA, K., Y. HASHIMOTO, and S. IWASAKI. 1994. Enhancement of phorbol ester-induced production of tumor necrosis factor α by thalidomide. Biochem. Biophys. Res. Commun. 199:455-460.
39. GUPTA, J. W., M. KUBIN, L. HARTMAN, M. CASSATELLA, and G. TRINCHIERI. 1992. Induction of expression of genes encoding components of the respiratory burst oxidase during differentiation of human myeloid cell lines induced by tumor necrosis factor and γ-interferon. Cancer Res. 52:2530-2537.
40. 2 oxidoreductase in human neutrophils after stimulation with phorbol myristate acetate. J. Biol. Chem. 265:924-930.
41. GORDON, G. B., S. P. SPIELBERG, D. A. BLAKE, and V. BALASUBRAMANIAN. 1981. Thalidomide teratogenesis: Evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci. U.S.A. 78:2545-2548.
42. ALTMANN, H. 1983. Poly-(ADP-Ribose-)Synthese und Regulationsstörungen bei Erkrankungen. Wien. klin. Wschr. 95:861-864.
43. MILLER, E. J., and R. K. RHODES. 1982. Preparation and characterization of the different types of collagen. Methods Enzymol. 82:33-64.